Stockscreener 앱 받기
2.81
4.10%
-0.12
시간 외 거래:
2.90
0.09
+3.20%
전일 마감가:
$2.93
열려 있는:
$2.92
하루 거래량:
17,632
Relative Volume:
0.56
시가총액:
$8.79M
수익:
-
순이익/손실:
$2.81M
주가수익비율:
-0.1958
EPS:
-14.3497
순현금흐름:
$7.14M
1주 성능:
-6.02%
1개월 성능:
-13.54%
6개월 성능:
-22.59%
1년 성능:
-46.90%
1일 변동 폭
$2.72
$2.92
1주일 범위
$2.72
$3.175
52주 변동 폭
$2.72
$5.76
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
명칭
Kiora Pharmaceuticals Inc
전화
781-788-8869
주소
332 ENCINITAS BOULEVARD, ENCINITAS
KPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.81 | 8.79M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
Kiora Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kiora Achieves Breakthrough Year: $3.6M Profit as Retinal Disease Pipeline Expands - Stock Titan
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Kiora Pharmaceuticals Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (KPRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting - Newsfile
Breakthrough Eye Treatment: Kiora's KIO-104 Could Prevent Post-Surgery Scarring - StockTitan
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 - MSN
Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 By Investing.com - Investing.com Nigeria
Patent Victory: Kiora's Eye Drug Gets 20-Year Protection, Phase 2 Trial Coming in 2025 - StockTitan
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 - Newsfile
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
Promising US Penny Stocks To Consider In January 2025 - Simply Wall St
3 US Penny Stocks With Market Cap Under $70M - Yahoo Finance
January 2025's Top US Penny Stocks To Consider - Yahoo Finance
Kiora Pharmaceuticals, Inc. Announces Promotion of Melissa Tosca to Chief Financial Officer - Marketscreener.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 5.9% – Here’s What Happened - Defense World
3 US Penny Stocks With Market Caps Under $200M - Simply Wall St
US Penny Stocks: 3 Picks With Market Caps Below $400M - Yahoo Finance
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Cerus And 2 Other US Penny Stocks With Promising Potential - Yahoo Finance
3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St
US Penny Stocks To Watch In January 2025 - Yahoo Finance
3 Promising US Penny Stocks With Market Caps Under $80M - simplywall.st
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy? - Defense World
Retinitis Pigmentosa Treatment Market Report: Detailed - openPR
Persistent Epithelial Defect Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Kiora Pharma, Combangio, Inc, Santen Pharmaceutical, Amber Ophthalmics, Noveome - The Globe and Mail
Persistent Epithelial Defect Market Statistics Expected - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eyegate Pharmaceuticals Receives Canadian Patent for Proprietary Iontophoretic Formulation and Use - Marketscreener.com
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Inc (KPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):